Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 69

Year

2024 1

2023 7

2022 11

2020 5

2019 5

2018 1

2017 2

2016 5

2015 3

2014 3

2013 2

2012 4

2011 2

2010 2

2009 11

2008 2

2007 3

open ︾

Keywords

apoptosis 4

immune checkpoint inhibitor 4

immunotherapy 3

COVID-19 2

cancer 2

cell cycle 2

drug resistance 2

hepatocellular carcinoma 2

hypertension 2

tyrosine kinase inhibitor 2

Hevea brasiliensis 1

ADAM10 inhibitor 1

AZD9291 1

Antibiotic adjuvant 1

BPTF 1

Barrier disruption 1

Btk inhibitor 1

CAR T-cell therapy 1

CHK1 1

Carbapenem-resistant 1

open ︾

Search scope:

排序： Display mode:

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Shuhang Wang,Yongping Song,Feifei Yan,Delong Liu

Frontiers of Medicine 2016, Volume 10, Issue 4, Pages 383-388 doi: 10.1007/s11684-016-0488-1

Abstract:

The tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are becoming theacquired resistance to AZD9291, EAI045 was discovered and recently reported to be an allosteric EGFR inhibitorresistance to the EGFR TKIs, as well as the latest development of EAI045 as a fourth-generation EGFR inhibitor

Keywords： EGFR tyrosine kinase inhibitor AZD9291 EAI045

HTML PDF Collect

Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

Amy Lee, Fa-Chyi Lee

Frontiers of Medicine 2020, Volume 14, Issue 3, Pages 273-283 doi: 10.1007/s11684-019-0728-2

Abstract: Up until 2017, treatment of advanced HCC was largely limited to sorafenib, an oral tyrosine kinase inhibitorAs of 2019, the US FDA has approved four oral tyrosine kinase inhibitors, two immune checkpoint inhibitorsThe use of immune checkpoint inhibitors in conjunction with oral tyrosine kinase inhibitors or anti-angiogenesis

Keywords： hepatocellular carcinoma tyrosine kinase inhibitor check point inhibitor anti-angiogenesis

HTML PDF Collect

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

Frontiers of Medicine 2019, Volume 13, Issue 4, Pages 427-437 doi: 10.1007/s11684-018-0672-6

Abstract: Tyrosine kinase and γ-secretase inhibitors are primarily used in the targeted therapy of DF.

Keywords： targeted therapy desmoid-type fibromatosis tyrosine kinase inhibitor γ-secretase inhibitor

HTML PDF Collect

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Frontiers of Medicine 2015, Volume 9, Issue 2, Pages 134-138 doi: 10.1007/s11684-015-0396-9

Abstract: In this review, we discuss the main known mechanisms of resistance to receptor tyrosine kinase inhibitorsconsider the problems of signaling pathway redundancy and how the activation of different receptor tyrosine

Keywords： targeted therapy drug resistance receptor tyrosine kinases cancer

HTML PDF Collect

Effect of inhibiting tyrosine kinase Src expression on protein phosphatase 2A and tau phosphorylation

LIU Rong, ZENG Ji, ZHOU Xinwen, WANG Jianzhi, PEI Jinjing

Frontiers of Medicine 2008, Volume 2, Issue 3, Pages 235-238 doi: 10.1007/s11684-008-0044-8

Abstract: The aim of this study is to investigate the effect of tyrosine kinase Src on Tyrosine 307(Y307) phosphorylation

Keywords： hyperphosphorylation PP2A activity cellular regulation siRNA siRNA transfection

HTML PDF Collect

Effects of phosphatidylinositol 3-kinase inhibitor on human cervical carcinoma cells

Yuan ZHANG MD , Xiaoyan ZHANG MM , Yanhui LI MM , Xuan DU MM , Zehua WANG MD, PhD , Hongbo WANG MD ,

Frontiers of Medicine 2009, Volume 3, Issue 3, Pages 341-346 doi: 10.1007/s11684-009-0067-9

Abstract: Phosphatidylinositol 3-kinase (PI3K) is a crucial cell survival pathway implicated in tumorigenesis becauseThis study was to investigate the regulation of proliferation and apoptosis by LY294002, an inhibitor

Keywords： human cervical cancer cells apoptosis phosphatidylinositol 3-kinase (PI3K)/Akt FLICE-like inhibitory

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6, Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: precursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2 inhibitor

Keywords： acute lymphoblastic leukemia molecular therapeutics targeted therapy tyrosine kinase inhibitors immunotherapy

HTML PDF Collect

Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety

Xiaojun Huang, Qian Jiang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang, Jianxiang Wang

Frontiers of Medicine 2019, Volume 13, Issue 3, Pages 344-353 doi: 10.1007/s11684-018-0639-7

Abstract: Dasatinib is a highly effective second-generation tyrosine kinase inhibitor used to treat chronic myeloid

Keywords： chronic myeloid leukemia (CML) dasatinib tyrosine kinase inhibitor long-term follow-up

HTML PDF Collect

Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?

Xu WANG MS, Xiao-Wei GONG MD, PhD, Yong JIANG MD, PhD, Yu-Hua LI PhD,

Frontiers of Medicine 2010, Volume 4, Issue 1, Pages 46-53 doi: 10.1007/s11684-010-0010-0

Abstract: Mitogen-activated protein kinase (MAPK) signaling pathway, one of the most important signaling pathwaysSo far, inhibitors specifically against each subfamilies of MAP kinase have been developed, while moreMost of the kinase inhibitors exert their functions in an ATP-competitive way or a non-ATP-competitiveinhibitors and their therapeutic roles in the treatment of diseases are helpful for the illumination of MAP kinase

Keywords： mitogen-activated protein kinase drug target inhibitor signal transduction disease

HTML PDF Collect

Proteomics study of Mycoplasma pneumoniae pneumonia reveals the Fc fragment of the IgG-binding protein as a serum biomarker and implicates potential therapeutic targets

Frontiers of Medicine 2022, Volume 16, Issue 3, Pages 378-388 doi: 10.1007/s11684-021-0840-y

Abstract: Among them, a mechanistic target of rapamycin kinase (mTOR) inhibitor, which is a macrolide compoundand a cell proliferation inhibitor, was the most promising candidate for targeting SMPP.

Keywords： pneumonia children proteomics Fc fragment of the IgG-binding protein mechanistic target of rapamycin kinaseinhibitor

HTML PDF Collect

Dual faces of SH2-containing protein-tyrosine phosphatase

Shuangwei Li, Diane DiFang Hsu, Hongyang Wang, Gen-Sheng Feng

Frontiers of Medicine 2012, Volume 6, Issue 3, Pages 275-279 doi: 10.1007/s11684-012-0216-4

Abstract:

PTPN11, which encodes tyrosine phosphatase Shp2, is a critical gene mediating cellular responses toAgainst original prediction as tumor suppressor for tyrosine phosphatases, PTPN11 was first

Keywords： PTPN11/Shp2 leukemia hepatocellular carcinoma mutation

HTML PDF Collect

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like

Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale

Frontiers of Medicine 2013, Volume 7, Issue 4, Pages 462-476 doi: 10.1007/s11684-013-0270-6

Abstract: Treating these CSC-like cells with gemcitabine alone and a combination of gemcitabine and the novel CHK1 inhibitor

Keywords： drug resistance cancer stem cell checkpoint kinase 1 (CHK1) PF-00477736 lung cancer tumorigenicity

HTML PDF Collect

The role of protein kinase C epsilon in neural signal transduction and neurogenic diseases

Yuan CHEN, Qi TIAN

Frontiers of Medicine 2011, Volume 5, Issue 1, Pages 70-76 doi: 10.1007/s11684-011-0119-9

Abstract:

Protein kinase C epsilon (PKC ?) is one of major isoforms in novel PKC family.

Keywords： protein kinase C ? signal transduction neurogenic disease

HTML PDF Collect

Renin--angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID

Frontiers of Medicine 2022, Volume 16, Issue 1, Pages 102-110 doi: 10.1007/s11684-021-0850-9

Abstract: January 2020 to March 2020 to investigate the association between the use of renin–angiotensin system inhibitorAssociations between the use of RAS-I (angiotensin-converting enzyme inhibitor (ACEI) or angiotensin

Keywords： COVID-19 RAS inhibitor hypertension all-cause mortality

HTML PDF Collect

Comparison between inhibitor and uncoupler for minimizing excess sludge production of an activated sludge

CHEN Guowei, XI Pengge, XU Deqian, YU Hanqing

Frontiers of Environmental Science & Engineering 2007, Volume 1, Issue 1, Pages 63-66 doi: 10.1007/s11783-007-0012-6

Abstract: minimization of excess sludge production, the reduction in the excess sludge production in the presence of an inhibitor

Keywords： uncoupling coefficient Cu minimization presence uncoupling

HTML PDF Collect

Title Author Date Type Operation

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Shuhang Wang,Yongping Song,Feifei Yan,Delong Liu

Journal Article

Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

Amy Lee, Fa-Chyi Lee

Journal Article

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

Journal Article

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Journal Article

Effect of inhibiting tyrosine kinase Src expression on protein phosphatase 2A and tau phosphorylation

LIU Rong, ZENG Ji, ZHOU Xinwen, WANG Jianzhi, PEI Jinjing

Journal Article

Effects of phosphatidylinositol 3-kinase inhibitor on human cervical carcinoma cells

Yuan ZHANG MD , Xiaoyan ZHANG MM , Yanhui LI MM , Xuan DU MM , Zehua WANG MD, PhD , Hongbo WANG MD ,

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety

Xiaojun Huang, Qian Jiang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang, Jianxiang Wang

Journal Article

Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?

Xu WANG MS, Xiao-Wei GONG MD, PhD, Yong JIANG MD, PhD, Yu-Hua LI PhD,

Journal Article

Proteomics study of Mycoplasma pneumoniae pneumonia reveals the Fc fragment of the IgG-binding protein as a serum biomarker and implicates potential therapeutic targets

Journal Article

Dual faces of SH2-containing protein-tyrosine phosphatase

Shuangwei Li, Diane DiFang Hsu, Hongyang Wang, Gen-Sheng Feng

Journal Article

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like

Journal Article

The role of protein kinase C epsilon in neural signal transduction and neurogenic diseases

Yuan CHEN, Qi TIAN

Journal Article

Renin--angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID

Journal Article

Comparison between inhibitor and uncoupler for minimizing excess sludge production of an activated sludge